Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idera Pharmaceuticals has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act for its worldwide licensing and collaboration agreement with Merck KGaA of Darmstadt, Germany, announced in December 2007.
Subscribe to our email newsletter
Under the agreement, Idera exclusively licensed the therapeutic oncology applications, excluding cancer vaccines, of its lead TLR9 agonists, IMO-2055 and IMO-2125. With the grant of HSR clearance, the agreement is now in effect and Idera is entitled to receive an upfront licensing fee of $40 million from Merck KGaA.